This week, significant insights regarding GLP-1 weight-loss medications were shared at an aging conference in Boston. Research from pharmaceutical giants Eli Lilly and Novo Nordisk indicates that individuals who are overweight or diabetic and use GLP-1 drugs exhibit a biological age that is approximately two to three years younger compared to those who receive a placebo. This finding has led some experts in the aging sector to label GLP-1s as potential longevity drugs, particularly for individuals struggling with obesity or diabetes. While the benefits of these drugs are becoming clearer, the side effects are still under investigation.
GLP-1 agonists, known for suppressing appetite, have gained approval for various conditions including diabetes, chronic kidney disease, and obesity management. They are also being explored for their potential to aid individuals with substance-use disorders and may offer benefits in treating neurodegenerative diseases and cancer. Recent data from a Gallup poll reveals a notable increase in usage, with 11% of Americans currently utilizing these drugs for weight loss, compared to just 3% in 2024. However, while they show promising efficacy, side effects remain a concern, and ongoing research is necessary to fully understand their implications.
Common side effects reported include gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation. There are also serious concerns regarding possible links to pancreatitis and gallbladder disease. In rare instances, patients have reported vision problems that may stem from nerve damage related to the drugs, leading to lawsuits against both Eli Lilly and Novo Nordisk. Furthermore, studies have suggested that GLP-1 usage could be associated with hair loss and nail disorders, although these effects appear to be relatively uncommon. The rising prescription rates among children aged eight to eleven are particularly alarming, especially in light of the recent World Health Organization guidelines that caution against pharmacological treatments for obesity in younger populations due to insufficient evidence regarding safety and efficacy. As research continues, the medical community remains vigilant in monitoring both the benefits and potential risks of these weight-loss medications.
Source: We’re still figuring out the side effects of GLP-1 weight-loss drugs via MIT Technology Review